Cointime

Glympse Bio

company

About

Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.

  • 1 - 10

Highlights

Total Funding Amount
$68.70M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$22M
Industries
Biotechnology,Health Care,Life Science,Medical Device,Nanotechnology
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis.

Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$68.70M
Glympse Bio has raised a total of $68.70M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 15, 2020 Series B $46.70M 1 — — Detail
Oct 9, 2018 Series A $22M 1 ARCH Venture Partners — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Glympse Bio is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners — Series B
Cointime
Chủ Đề
Công Ty